Lv35
220 积分 2025-03-27 加入
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
6天前
已完结
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy
8天前
已完结
Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease
11天前
已关闭
IgA Nephropathy
11天前
已完结
IgA nephropathy
11天前
已关闭
IgA Nephropathy
11天前
已完结
IgA Nephropathy
11天前
已完结
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
12天前
已完结
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
13天前
已完结
The landscape for radioligand therapies in oncology
13天前
已关闭
皖公网安备34019202002308
